-

PLAB Investor Alert: Levi & Korsinsky Investigates Photronics (PLAB) for Potential Securities Fraud

Photronics guided Q2 non-GAAP EPS of $0.49 to $0.55 on February 27, 2026; actual non-GAAP EPS came in at $0.42 per diluted share -- and cost pressures that drove the miss were absent from the Company's forward outlook.

NEW YORK--(BUSINESS WIRE)--Shareholders who held Photronics (NASDAQ: PLAB) stock lost more than 30% of their investment today after the Company reported fiscal Q2 results that fell below its own guidance. Those who purchased PLAB shares and suffered a loss are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

On February 27, 2026, President & CFO Eric Rivera guided investors to expect fiscal Q2 non-GAAP diluted EPS of $0.49 to $0.55 and operating margins of 22% to 24%. Rivera acknowledged that the Company operates with only 1-to-3 weeks of backlog visibility. The guidance did not quantify known cost headwinds, including accelerated depreciation tied to end-of-life tool purchases and rising capital expenditures. CEO George Macricostas told investors the Company was "optimistic" that "high-end strength will continue" to offset seasonal effects from Chinese New Year.

When Q2 results arrived on May 28, 2026, non-GAAP diluted EPS was $0.42 -- well below the low end of the projected range. Revenue of $209.9 million landed beneath the Company's prior quarterly expectations for $212 to $220 million. PLAB shares fell approximately 30% in a single session.

PLAB investors who lost money can click here to get additional information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the PLAB Investigation

Q: What is the PLAB securities fraud investigation about? A: A securities fraud investigation has been initiated concerning Photronics (NASDAQ: PLAB) regarding potentially materially false and misleading statements. Shares fell approximately 30% after the Company reported Q2 results below its own guidance, causing significant losses for shareholders.

Q: Who is eligible to participate in the PLAB investigation? A: Investors who purchased PLAB stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do PLAB investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.

Q: What if I already sold my PLAB shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought PLAB and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NASDAQ:PLAB

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

GIL Investor Alert: Levi & Korsinsky Investigates Gildan Activewear (GIL) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders who held Gildan Activewear (NYSE: GIL) lost nearly 19% of their investment value today after Jehoshaphat Research published allegations that Gildan had been stuffing distributor channels with approximately $510 million in excess inventory, a condition never referenced in the Company's forward guidance or outlook statements. Those who lost money on GIL are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi,...

NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP highlights the contrast between Nano-X Imaging Ltd.'s (NASDAQ: NNOX) public commitments and its actual results. A securities class action has been filed on behalf of investors who purchased NNOX securities between March 31, 2025 and April 17, 2026. Find out if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.Nano-X told shareholders it was building a "highly efficient and scala...

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who lost money on NMRA are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com...
Back to Newsroom